OR WAIT null SECS
March 29, 2018
The acquisition strengthens Celgene’s position in the global cellular immunotherapy space.
The companies will co-develop and co-promote a CAR T cell therapy in the United States.
March 28, 2018
Takeda is considering approaching Shire with a possible offer.
March 27, 2018
In a $13-billion transaction, GSK will purchase Novartis’ share of the Consumer Healthcare Joint Venture.
March 26, 2018
Hitachi will manufacture regenerative medicines developed by Daiichi Sankyo and SanBio Group.
March 23, 2018
The collaboration between the two companies aims to finish all necessary work needed to file for a first-in-human study by early 2019.
March 22, 2018
Helsinn will acquire the global rights to Valchlor/Ledaga (mechlorethamine/chlormethine), a topical skin-cancer drug, from Actelion Pharmaceuticals.
March 19, 2018
Biogen will acquire an AMPA receptor potentiator for cognitive impairment associated with schizophrenia in a deal worth approximately $590 million.
The companies intend to jointly develop and commercialize Lenvima (lenvatinib mesylate) as a monotherapy and an in-combination therapy for treating multiple cancer types.
March 08, 2018
Under this agreement, the companies will develop in parallel an antibody drug candidate and cell lines for other potential candidates.